A new optimized formulation of cationic solid lipid nanoparticles intended for gene delivery: Development, characterization and DNA binding efficiency of TCERG1 expression plasmid

International Journal of Pharmaceutics

Volumn 473, Issue 1-2, 2014, Pages 270-279

  Fàbregas, Anna ^a   Sánchez Hernández, Noemí ^b   Ticó, Josep Ramon ^a   García Montoya, Encarna ^a   Pérez Lozano, Pilar ^a   Suñé Negre, Josep M ^a   Hernández Munain, Cristina ^b   Suñé, Carlos ^b   Miñarro, Montserrat ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Cationic solid lipid nanoparticles development; Cell viability; DNA binding efficiency; Plasmid DNA; Solid lipid nanoparticles characterization

Indexed keywords

DRUG CARRIER; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; LIPID; LIPOPLEX; OCTADECYLAMINE; PLASMID DNA; POLOXAMER; PROTEIN; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRANSCRIPTION ELONGATION REGULATOR 1; UNCLASSIFIED DRUG; WATER; DNA; NANOPARTICLE; TCERG1 PROTEIN, HUMAN; TRANSCRIPTION ELONGATION FACTOR;

AGAR GEL ELECTROPHORESIS; ARTICLE; ATOMIC FORCE MICROSCOPY; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CHEMICAL INTERACTION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DNA BINDING; FREEZE DRYING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PLASMID; PRIORITY JOURNAL; RNA SPLICING; SURFACE CHARGE; SYNTHESIS; TRANSCRIPTION ELONGATION; X RAY DIFFRACTION; X RAY PHOTOELECTRON SPECTROSCOPY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE TRANSFER; GENETICS; HEK293 CELL LINE; MEDICINAL CHEMISTRY;

CALORIMETRY, DIFFERENTIAL SCANNING; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DNA; GENE TRANSFER TECHNIQUES; HEK293 CELLS; HUMANS; LIPIDS; MASS SPECTROMETRY; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PHOTOELECTRON SPECTROSCOPY; PLASMIDS; TRANSCRIPTIONAL ELONGATION FACTORS; X-RAY DIFFRACTION;

EID: 84905055523     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.06.022     Document Type: Article

References (38)

1. R. Abbasalipourkabir, A. Salehzadeh, and R. Abdullah Cytotoxicity effect of solid lipid nanoparticles on human breast cancer cell lines Biotechnology 10 2011 528 533
2. M. Arango, S. Holbert, and D. Zala et al. CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant Huntingtin neurotoxicity J. Neurosci. 26 2006 4649 4659 (Pubitemid 44315366)
3. H. Bunjes Structural properties of solid lipid based colloidal drug delivery systems Curr. Opin. Colloid Interface Sci. 16 2011 405 411
4. R.S. Chang, M.S. Suh, and S. Kim et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA Biomaterials 32 2011 9785 9795
5. D. Cheng, J. Côté, S. Shaaban, and M.T. Bedford The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing Mol. Cell. 25 2007 71 83 (Pubitemid 46049059)
6. S.H. Choi, S.-E. Jin, and M.-K. Lee et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells Eur. J. Pharm. Biopharm. 68 2008 545 554 (Pubitemid 351318200)
7. M. Coiras, M. Montes, and I. Montanuy et al. Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication Retrovirology 10 2013 1 18
8. S. Doktorovova, R. Shegokar, and E. Rakovsky et al. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies Int. J. Pharm. 420 2011 341 349
9. P. Ekambaran, A. Abdul Hasan Sathali, and K. Priyanka Solid lipid nanoparticles: a review Sci. Rev. Chem. Commun. 1 2012 80
10. A.C. Goldstrohm, A.L. Greenleaf, and M.A. Garcia-Blanco Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing Gene 277 2001 31 47 (Pubitemid 32973194)
11. A.V. Heydenreich, R. Westmeier, N. Pedersen, H.S. Poulsen, and H.G. Kristensen Preparation and purification of cationic solid lipid nanospheres - effects on particle size, physical stability and cell toxicity Int. J. Pharm. 254 2003 83 87 (Pubitemid 36259816)
12. S. Holbert, I. Denghien, and T. Kiechle et al. The Gln-Ala repeat transcriptional activator CA150 interacts with Huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis Proc. Natl. Acad. Sci. U. S. A. 98 2001 1811 1816 (Pubitemid 32165580)
13. D. Hou, C. Xie, K. Huang, and C. Zhu The production and characteristics of solid lipid nanoparticles (SLNs) Biomaterials 24 2003 1781 1785 (Pubitemid 36184733)
14. S.-E. Jin, C.-K. Kim, and Y.-B. Kim Cellular delivery of cationic lipid nanoparticle-based SMAD3 antisense oligonucleotides for the inhibition of collagen production in keloid fibroblasts Eur. J. Pharm. Biopharm. 2014 10.1016/j.ejpb.2012.05.015
15. S. Kumar, and J.K. Randhawa High melting lipid based approach for drug delivery: solid lipid nanoparticles Mater. Sci. Eng. C 33 2013 1842 1852
16. M.J. Lawrence, and G.D. Rees Microemulsion-based media as novel drug delivery systems Adv. Drug Deliv. Rev. 6 2012 89 121
17. K.-T. Lin, R.-M. Lu, and W.-Y. Tarn The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo Mol. Cell Biol. 24 2004 9176 9185 (Pubitemid 39313919)
18. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177 (Pubitemid 30326695)
19. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196 (Pubitemid 32324113)
20. M. Montes, S. Becerra, M. Sánchez-Álvarez, and C. Suñé Functional coupling of transcription and splicing Gene 501 2012 104 117
21. M. Montes, A. Cloutier, and N. Sanchez-Hernandez et al. TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription Mol. Cell Biol. 32 2012 751 762
22. C. Olbrich, U. Bakowsky, C.-M. Lehr, R.H. Müller, and C. Kneuer Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA J. Control. Release 77 2001 345 355 (Pubitemid 33145485)
23. J.L. Pearson, T.J. Robinson, M.J. Muñoz, A.R. Kornblihtt, and M.A. Garcia-Blanco Identification of the cellular targets of the transcription factor TCERG1 reveals a prevalent role in mRNA processing J. Biol. Chem. 283 2008 7949 7961
24. N. Pedersen, S. Hansen, A.V. Heydenreich, H.G. Kristensen, and H.S. Poulsen Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands Eur. J. Pharm. Biopharm. 62 2006 155 162 (Pubitemid 43143267)
25. C. Rudolph, U. Schillinger, and A. Ortiz et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo Pharm. Res. 21 2004 1662 1669 (Pubitemid 41184398)
26. M. Sánchez-Alvarez, A.C. Goldstrohm, M.A. Garcia-Blanco, and C. Suñé Human transcription elongation factor CA150 localizes to splicing factor-rich nuclear speckles and assembles transcription and splicing components into complexes through its amino and carboxyl regions Mol. Cell Biol. 26 2006 4998 5014 (Pubitemid 43955814)
27. M. Sánchez-Alvarez, M. Montes, N. Sánchez-Hernández, C. Hernández-Munain, and C. Suñé Differential effects of sumoylation on transcription and alternative splicing by transcription elongation regulator 1 (TCERG1) J. Biol. Chem. 285 2010 15220 15233
28. C. Schwarz, and W. Mehnert Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN) Int. J. Pharm. 157 1997 171 179 (Pubitemid 27471169)
29. M. Schoenitz, S. Joseph, A. Nitz, H. Bunjes, and S. Scholl Controlled polymorphic transformation of continuously crystallized solid lipid nanoparticles in a microstructured device: a feasibility study Eur J. Pharm. Biopharm. 2013 49
30. P. Severino, S.C. Pinho, E.B. Souto, and M.H.A. Santana Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles Colloids Surf. B Biointerfaces 86 2011 125 130
31. M.J. Smith, S. Kulkarni, and T. Pawson FF domains of CA150 bind transcription and splicing factors through multiple weak interactions Mol. Cell Biol. 24 2004 9274 9285 (Pubitemid 39391666)
32. C. Suñe, T. Hayashi, and Y. Liu et al. CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription Mol. Cell Biol. 17 1997 6029 6039 (Pubitemid 27411111)
33. K. Tabatt, M. Sameti, C. Olbrich, R.H. Müller, and C.-M. Lehr Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer Eur. J. Pharm. Biopharm. 57 2004 155 162 (Pubitemid 38283690)
34. E. Vighi, B. Ruozi, M. Montanari, R. Battini, and E. Leo Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid Eur. J. Pharm. Biopharm. 67 2007 320 328 (Pubitemid 47211893)
35. E. Vighi, B. Ruozi, M. Montanari, R. Battini, and E. Leo pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles Int. J. Pharm. 389 2010 254 261
36. E. Vighi, M. Montanari, M. Hanuskova, V. Iannuccelli, G. Coppi, and E. Leo Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector Int. J. Pharm. 440 2013 161 169
37. Y.H. Yu, E. Kim, and D.E. Park et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA Eur. J. Pharm. Biopharm. 80 2012 268 273 10.1016/j.ejpb.2011.11.002
38. J. Zabner, A.J. Fasbender, T. Moninger, K.A. Poellinger, and M.J. Welsh Cellular and molecular barriers to gene transfer by a cationic lipid J. Biol. Chem. 270 1995 18997 19007